Severe Skin Toxicity
Severe Skin Toxicity - Related Videos
06:21
Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
0 Views •
Cited by 13 •
2016
We present a diffuse optical spectroscopic (DOS) approach that provides quantitative optical biomarkers of skin response to radiation. We describe DOS instrumentation design, optical parameters extraction algorithms and the animal handling procedures required to yield representative data from a pre-clinical mouse model of radiation induced erythema.
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
10:00
A Contusion Model of Severe Spinal Cord Injury in Rats
0 Views •
Cited by 41 •
2013
A contusion model of severe spinal cord injury is described. Detailed pre-operative, operative and post-operative steps are described to obtain a consistent model.
13:59
Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
0 Views •
Cited by 76 •
2010
The intensely studied nematode worm Caenorhabditis elegans can be transgenically engineered to express the human β-amyloid peptide (Aβ). Induced expression of Aβ in C. elegans muscle leads to a rapid, reproducible paralysis phenotype that can be used to monitor treatments that modulate Aβ toxicity.
09:06
Growth Assays to Assess Polyglutamine Toxicity in Yeast
0 Views •
Cited by 3 •
2012
This manuscript describes three complementary protocols for assessing the toxicity of polyglutamine (polyQ)-expansion proteins in the yeast Saccharomyces cerevisiae. These protocols can easily be modified to monitor the toxicity of other misfolded proteins in yeast.
FAQs
Two broad mechanisms are described. Some exposures injure skin tissue directly, while others activate immune cells that attack keratinocytes, the predominant cells of the outer skin layer. This immune-mediated injury can amplify inflammation and contribute to blistering, epidermal detachment, and mucosal lesions. Recognizing the likely mechanism helps clinicians interpret the clinical pattern and assess the suspected cause.
Keratinocytes become important when activated immune cells target them during an immune-mediated reaction. Damage to these cells can disrupt the epidermis, the skin’s outer layer, and is associated with extensive inflammation, blister formation, and epidermal detachment. Because these changes may occur alongside mucosal lesions, their presence contributes to recognizing a serious drug-related or treatment-related skin reaction.
Clinical patterns such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and severe drug eruptions provide important clues during medical assessment. Identifying these patterns can help clinicians connect the reaction with a suspected medication or other trigger and recognize the possibility of progression. That information supports timely action, including removal of the causative agent and specialist management.
Prompt medical assessment is essential because severe skin toxicity can be potentially life-threatening. Once a causative agent is suspected, rapid withdrawal is a central priority, followed by supportive care and specialist management. Acting quickly may help prevent continued exposure while clinicians address the extensive inflammation, blistering, epidermal detachment, or mucosal involvement associated with serious reactions.
Withdrawal alone does not complete management. Supportive care and specialist management are identified as necessary components for patients with serious skin reactions, particularly when inflammation, blistering, epidermal detachment, or mucosal lesions are present. Together with prompt assessment, these measures address the immediate clinical burden and are intended to reduce complications while the reaction is evaluated.
Pharmacovigilance, the systematic attention to treatment-related safety, helps identify and understand severe skin toxicity associated with medications and cancer treatments. Recording suspected triggers and recognizing recurring reaction patterns can strengthen knowledge of treatment-related risk. In medicine, this information supports safer use of therapies, reinforces early recognition, and contributes to efforts to reduce complications.